RISPERDAL

LOE Approaching

risperidone

NDAORALSOLUTION
Approved
Jun 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
139

Mechanism of Action

unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite,…

Pharmacologic Class:

Atypical Antipsychotic

Clinical Trials (5)

NCT04940039Phase 4Completed

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

Started Jul 2021
93 enrolled
Schizophrenia
NCT04418466Phase 1/2Completed

Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant

Started Apr 2021
NCT03978832Phase 4Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Started Jun 2019
69 enrolled
Schizophrenia
NCT03713658Phase 4Completed

A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities

Started Oct 2018
34 enrolled
Schizophrenia
NCT03390712N/AUnknown

Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection

Started Jan 2018
328 enrolled
Schizophrenia Spectrum and Other Psychotic Disorders